{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=53", "query": { "condition": "Carcinoma of Head/Neck", "page": 53 }, "page_size": 10 }, "pagination": { "page": 53, "page_size": 10, "total_count": 1995, "total_pages": 200, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=54&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=52&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T23:31:00.044Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05283226", "title": "Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma", "Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "NRC-2694-A", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NATCO Pharma Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2022-09-30", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-25T23:31:00.044Z", "location_count": 10, "location_summary": "Fullerton, California • Los Angeles, California • Boca Raton, Florida + 7 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05283226" }, { "nct_id": "NCT02628535", "title": "Safety Study of MGD009 in B7-H3-expressing Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelioma", "Bladder Cancer", "Melanoma", "Squamous Cell Carcinoma of the Head and Neck", "Non Small Cell Lung Cancer", "Clear Cell Renal Cell Carcinoma", "Ovarian Cancer", "Thyroid Cancer", "Breast Cancer", "Pancreatic Cancer", "Prostate Cancer", "Colon Cancer", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "MGD009", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2015-09", "completion_date": "2019-11-25", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-10-25T23:31:00.044Z", "location_count": 14, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02628535" }, { "nct_id": "NCT06788990", "title": "FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Metastatic Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Ficerafusp alfa", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bicara Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 650, "start_date": "2025-01-28", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-25T23:31:00.044Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06788990" }, { "nct_id": "NCT02762513", "title": "Expansion Trial for Axitinib In Head And Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2016-08-30", "completion_date": "2020-04-09", "has_results": true, "last_update_posted_date": "2021-05-05", "last_synced_at": "2026-10-25T23:31:00.044Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02762513" }, { "nct_id": "NCT00036790", "title": "Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Colorectal Cancer", "Head and Neck Cancer", "Leukemia", "Lung Cancer", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic/Myeloproliferative Diseases", "Prostate Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "motexafin gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-25T23:31:00.044Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Madison, Wisconsin", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036790" }, { "nct_id": "NCT00601913", "title": "Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "protein analysis", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "liquid chromatography", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 24, "start_date": "2008-03", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2018-07-05", "last_synced_at": "2026-10-25T23:31:00.044Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00601913" }, { "nct_id": "NCT05156060", "title": "Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Locally Advanced Head and Neck Carcinoma" ], "interventions": [ { "name": "Gabapentin", "type": "DRUG" }, { "name": "Ketamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Natalie Lockney", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 64, "start_date": "2022-01-24", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2024-10-21", "last_synced_at": "2026-10-25T23:31:00.044Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05156060" }, { "nct_id": "NCT01726582", "title": "Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (\"Personalized Medicine\")", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Milestone 1: Targeted chemotherapy prior to surgery", "type": "DRUG" }, { "name": "Milestone 2: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 3: Targeted chemotherapy prior to surgery", "type": "DRUG" }, { "name": "Milestone 3: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery", "type": "DRUG" }, { "name": "Milestone 4: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 5: Targeted chemotherapy after surgery", "type": "DRUG" }, { "name": "Milestone 5: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 6: Gemcitabine after surgery", "type": "DRUG" }, { "name": "Milestone 6: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 7: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 8: Targeted chemotherapy after surgery", "type": "DRUG" }, { "name": "Milestone 9: Gemcitabine after surgery", "type": "DRUG" }, { "name": "Milestone 10: No additional therapy after surgery", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2011-11", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-10-25T23:31:00.044Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Milwaukee, Wisconsin", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01726582" }, { "nct_id": "NCT00507858", "title": "Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2005-09", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2011-09-23", "last_synced_at": "2026-10-25T23:31:00.044Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00507858" }, { "nct_id": "NCT01283178", "title": "Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Salivary Gland Squamous Cell Carcinoma", "Stage II Salivary Gland Cancer", "Stage II Squamous Cell Carcinoma of the Hypopharynx", "Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage II Squamous Cell Carcinoma of the Oropharynx", "Stage II Verrucous Carcinoma of the Oral Cavity", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Verrucous Carcinoma of the Oral Cavity" ], "interventions": [ { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "image-guided adaptive radiation therapy", "type": "RADIATION" }, { "name": "3'-deoxy-3'-[18F]fluorothymidine", "type": "OTHER" }, { "name": "positron emission tomography/computed tomography", "type": "PROCEDURE" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 3, "start_date": "2011-07", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2016-10-31", "last_synced_at": "2026-10-25T23:31:00.044Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01283178" } ] }